X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
platinum-free interval (36) 36
oncology (32) 32
chemotherapy (28) 28
ovarian cancer (28) 28
humans (27) 27
female (26) 26
index medicus (26) 26
middle aged (20) 20
aged (19) 19
ovarian neoplasms - drug therapy (17) 17
adult (15) 15
cancer (15) 15
neoplasm recurrence, local - drug therapy (14) 14
antineoplastic combined chemotherapy protocols - therapeutic use (13) 13
obstetrics & gynecology (13) 13
carboplatin (12) 12
pegylated liposomal doxorubicin (12) 12
care and treatment (11) 11
disease-free survival (11) 11
paclitaxel (11) 11
recurrence (11) 11
aged, 80 and over (10) 10
trabectedin (10) 10
cisplatin (9) 9
cancer patients (8) 8
carcinoma (8) 8
medicine & public health (8) 8
retrospective studies (8) 8
treatment outcome (8) 8
diseases (7) 7
doxorubicin - analogs & derivatives (7) 7
drug resistance, neoplasm (7) 7
phase-ii (7) 7
relapse (7) 7
survival rate (7) 7
women (7) 7
antineoplastic agents - therapeutic use (6) 6
antineoplastic combined chemotherapy protocols - administration & dosage (6) 6
cancer research (6) 6
carboplatin - administration & dosage (6) 6
carcinoma, ovarian epithelial (6) 6
doxorubicin - administration & dosage (6) 6
epithelial ovarian (6) 6
gynecologic-oncology-group (6) 6
hematology, oncology and palliative medicine (6) 6
neoplasms, glandular and epithelial - drug therapy (6) 6
organoplatinum compounds - administration & dosage (6) 6
pharmacology & pharmacy (6) 6
polyethylene glycols - administration & dosage (6) 6
prognosis (6) 6
survival (6) 6
topotecan (6) 6
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
combination (5) 5
dioxoles - administration & dosage (5) 5
drug administration schedule (5) 5
neoplasm recurrence, local - pathology (5) 5
neoplasm staging (5) 5
ovarian neoplasms - mortality (5) 5
ovarian neoplasms - pathology (5) 5
patients (5) 5
phase-ii trial (5) 5
platinum (5) 5
recurrent (5) 5
tetrahydroisoquinolines - administration & dosage (5) 5
therapy (5) 5
trial (5) 5
analysis (4) 4
bevacizumab (4) 4
cervical cancer (4) 4
cisplatin - administration & dosage (4) 4
clinical trials (4) 4
doxorubicin - adverse effects (4) 4
gemcitabine (4) 4
health aspects (4) 4
neoplasm recurrence, local - mortality (4) 4
obstetrics and gynecology (4) 4
original (4) 4
ovarian carcinoma (4) 4
pharmacology/toxicology (4) 4
platinum-based chemotherapy (4) 4
polyethylene glycols - adverse effects (4) 4
recurrent ovarian cancer (4) 4
second-line chemotherapy (4) 4
time factors (4) 4
uterine cervical neoplasms - drug therapy (4) 4
article (3) 3
cancer therapies (3) 3
carboplatin - adverse effects (3) 3
carcinoma, squamous cell - drug therapy (3) 3
dioxoles - adverse effects (3) 3
drug resistance (3) 3
endocrine system diseases (3) 3
genes, brca1 (3) 3
genes, brca2 (3) 3
gynecology and obstetrics (3) 3
medical prognosis (3) 3
medicine (3) 3
multivariate analysis (3) 3
neoplasm recurrence, local - therapy (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Oncology, ISSN 0923-7534, 2011, Volume 22, Issue 1, pp. 39 - 48
Journal Article
Cancer, ISSN 0008-543X, 09/2017, Volume 123, Issue 18, pp. 3450 - 3459
Journal Article
Annals of Oncology, ISSN 0923-7534, 2011, Volume 22, Issue 1, pp. 49 - 58
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2017, Volume 146, Issue 1, pp. 58 - 63
Journal Article
European Journal of Gynaecological Oncology, ISSN 0392-2936, 2014, Volume 35, Issue 3, pp. 224 - 229
Journal Article
The Oncologist, ISSN 1083-7159, 04/1999, Volume 4, Issue 2, pp. 87 - 94
Although the combination of platinum and paclitaxel offers effective chemotherapy for advanced ovarian cancer, the majority of women will eventually relapse... 
Second‐line chemotherapy | Topotecan | Relapsed or recurrent disease | Platinum‐free interval (PFI) | Ovarian cancer | Second-line chemotherapy | Platinum-free interval (PFI)
Journal Article
Journal Article
Archives of Gynecology and Obstetrics, ISSN 0932-0067, 2/2011, Volume 283, Issue 2, pp. 361 - 367
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2004, Volume 94, Issue 1, pp. 67 - 73
Objective. Topotecan, a novel topoisomerase-I inhibitor, is an active agent of second-line chemotherapy for extending the platinum-free interval (PFI) and... 
Platinum-free interval | Topotecan | Cisplatin resistance | MTT assay | DRUG | CARBOPLATIN | cisplatin resistance | PHASE-II | CHEMOTHERAPY | RESISTANT OVARIAN | PACLITAXEL | OBSTETRICS & GYNECOLOGY | platinum-free interval | THERAPY | CISPLATIN | ONCOLOGY | CARCINOMA | topotecan
Journal Article
Oncotarget, ISSN 1949-2553, 12/2018, Volume 9, Issue 101, pp. 37581 - 37588
The EXTREME protocol is the standard of care for recurrent or metastatic head and neck squamous-cell carcinoma (R/M HNSCC) in first line. Beyond the first-line... 
EXTREME | Platinum free Interval | Re-challenge | HNSCC
Journal Article
Opuholi Ženskoj Reproduktivnoj Sistemy, ISSN 1994-4098, 07/2014, Issue 1, pp. 113 - 118
The efficacy and safety of intravenous topotecan (hycamtin) given in a dose of 4 mg/m2 on days of 1, 8, 15 of a 28-day cycle of its therapy were evaluated in... 
relapse-free interval | platinum-free interval | disseminated ovarian cancer | topotecan
Journal Article
Journal Article
Future Oncology, ISSN 1479-6694, 10/2017, Volume 13, Issue 23S, pp. 23 - 29
Trabectedin + pegylated liposomal doxorubicin (PLD) offers a well tolerated and effective nonplatinum, nontaxane alternative for treatment of ovarian cancer... 
treatment-free interval | sequence effect | trabectedin | recurrent ovarian cancer | CELLS | CARBOPLATIN | PLD | COMBINATION | ANTITUMOR | PLATINUM-FREE INTERVAL | CHEMOTHERAPY | PACLITAXEL | ONCOLOGY | RESISTANCE | HYPERSENSITIVITY REACTIONS
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2015, Volume 137, Issue 3, pp. 386 - 391
Abstract Background Veliparib is a potent small molecule inhibitor of PARP-1/2, which is cytotoxic in tumor cells with deficiencies in BRCA1 or BRCA2 . We... 
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | BRCA1, BRCA2 mutation | Toxicity | Veliparib | PARP inhibitor | Phase II trial | Ovarian cancer | MULTICENTER | OPEN-LABEL | COMBINATION | PLATINUM-FREE INTERVAL | SOMATIC MUTATIONS | OBSTETRICS & GYNECOLOGY | OLAPARIB | ONCOLOGY | RESISTANCE | HOMOLOGOUS RECOMBINATION | REFRACTORY SOLID TUMORS | POLY(ADP-RIBOSE) POLYMERASE INHIBITOR | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Ovarian Neoplasms - genetics | BRCA1 Protein - genetics | Neoplasms, Glandular and Epithelial - genetics | Peritoneal Neoplasms - drug therapy | Peritoneal Neoplasms - genetics | Fallopian Tube Neoplasms - genetics | Neoplasms, Glandular and Epithelial - drug therapy | Aged, 80 and over | Carcinoma, Ovarian Epithelial | Genes, BRCA2 | Germ-Line Mutation | Adult | Female | Neoplasm Recurrence, Local - genetics | Aged | Genes, BRCA1 | Benzimidazoles - adverse effects | Ovarian Neoplasms - drug therapy | BRCA2 Protein - genetics | Benzimidazoles - therapeutic use | Fallopian Tube Neoplasms - drug therapy | Medical research | Cancer patients | Care and treatment | Gene mutations | Analysis | Medicine, Experimental | Genetic aspects | Cancer | Chemotherapy | Clinical trials | Index Medicus | toxicity | BRCA2 mutation | ovarian cancer | veliparib | BRCA1
Journal Article
Oncology Letters, ISSN 1792-1074, 01/2018, Volume 15, Issue 1, pp. 588 - 591
Journal Article